Diabetes Care · 2012 · 301 citations · 20 references
This novel IL-1β-neutralizing antibody improved glycemia, possibly via restored insulin production and action, and reduced inflammation in patients with type 2 diabetes. This therapeutic agent may be able to be used on a once-every-month or longer schedule.
20
Diagnosis and Classification of Diabetes Mellitus
Diabetes Care · 2010 · 14K citations · Full text
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Bolormaa Vandanmagsar, Yun‐Hee Youm, Anthony Ravussin et al. · Nature Medicine · 2011 · 2.5K citations · Full text
Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
Claus M. Larsen, Mirjam Faulenbach, Allan Vaag et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text
Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Haitao Wen, Denis Gris, Yu L. Lei et al. · Nature Immunology · 2011 · 1.7K citations · Full text